Scholarlink

Background <p>The growing trend of delayed childbearing in contemporary society has made fertility preservation a significant issue, prompting the search for diverse therapeutic options. Conversely, moxibustion is gaining increasing attention as a potential non-pharmacological therapy for supporting reproductive health.</p> Methods <p>Mice aged 2 to 14&#xa0;months were assessed for ovarian function detection to determine the age of reproductive senescence and to identify the optimal time for moxibustion intervention to delay senescence. Oocyte quality and mitochondrial function assessments were conducted to investigate the role of mitochondrial biogenesis in ovarian aging and the underlying mechanisms following moxibustion intervention.</p> Results <p>Mice aged 10&#xa0;months demonstrated ovarian dysfunction associated with aging. Moxibustion significantly elevated hormone levels, increased the number of growing follicles, enhanced embryo implantation and viable birth rates, and reduced embryonic mortality in aging mice. The most pronounced effects were observed in 10-month-old mice. These beneficial outcomes might be linked to improved oocyte quality. Crucially, moxibustion positively increased mitochondrial quantity, enhanced mitochondrial quality, and influenced mitochondrial biogenesis, an effect comparable to that of the peroxisome proliferator‐activated receptor γ coactivator 1α (PGC-1α) agonist valproic acid. Furthermore, the beneficial effects of moxibustion were partially attenuated by a PGC-1α inhibitor.</p> Conclusions <p>Moxibustion, as a non-pharmacological intervention, may mitigate ovarian aging and serve as an effective therapeutic strategy for extending human fertility.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Moxibustion delays ovarian aging by regulating mitochondrial biogenesis and improving oocyte quality

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月10日

查看全文
  • Yaoli Yin,
  • Yan Xu,
  • Zemin Li,
  • Meilin Chen,
  • Ziwei Song,
  • Hongxiao Li,
  • Ge Lu,
  • Meihong Shen

摘要

Background

The growing trend of delayed childbearing in contemporary society has made fertility preservation a significant issue, prompting the search for diverse therapeutic options. Conversely, moxibustion is gaining increasing attention as a potential non-pharmacological therapy for supporting reproductive health.

Methods

Mice aged 2 to 14 months were assessed for ovarian function detection to determine the age of reproductive senescence and to identify the optimal time for moxibustion intervention to delay senescence. Oocyte quality and mitochondrial function assessments were conducted to investigate the role of mitochondrial biogenesis in ovarian aging and the underlying mechanisms following moxibustion intervention.

Results

Mice aged 10 months demonstrated ovarian dysfunction associated with aging. Moxibustion significantly elevated hormone levels, increased the number of growing follicles, enhanced embryo implantation and viable birth rates, and reduced embryonic mortality in aging mice. The most pronounced effects were observed in 10-month-old mice. These beneficial outcomes might be linked to improved oocyte quality. Crucially, moxibustion positively increased mitochondrial quantity, enhanced mitochondrial quality, and influenced mitochondrial biogenesis, an effect comparable to that of the peroxisome proliferator‐activated receptor γ coactivator 1α (PGC-1α) agonist valproic acid. Furthermore, the beneficial effects of moxibustion were partially attenuated by a PGC-1α inhibitor.

Conclusions

Moxibustion, as a non-pharmacological intervention, may mitigate ovarian aging and serve as an effective therapeutic strategy for extending human fertility.

Graphical Abstract